Clinical trial NCT01370733: Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder
Official title: Evaluation of Low Emission NeoSync EEG Synchronized TMS Technology for the Treatment of Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Sham-Controlled, Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Major Depressive Disorder
Keywords: TMS,
MDD,
Depression,
sTMS,
NEST,
NeoSync,
EEG,
synchronous,
non-invasive neuromodulation,
transcranial magnetic stimulation,
antidepressant,
Lead sponsor: Wave Neuroscience
Sponsor class: INDUSTRY
First posted: 2011-06-10
Enrollment: 202
Sex: ALL
Minimum age (years): 22
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is designed to evaluate the safety and efficacy of synchronized transcranial magnetic stimulation (sTMS) using the NeoSync EEG Synchronized TMS device (NEST) in subjects with Major Depressive Disorder. This is a multicenter study in which subjects will be randomized to receive treatment 5 days per week for 6 weeks. Subjects who complete 6 weeks of double-blind treatment may be eligible to receive up to four weeks of open label sTMS therapy or antidepressant medications during the follow-up phase of the study. Follow-up evaluation visits will be conducted during those four weeks, with the frequency of the visits determined by the treatment choice during that timeframe.

Detailed description: Major Depressive Disorder (MDD) is a mental disorder associated with significant functional impairment and disability. Affected individuals present with depressed mood, loss of interest or pleasure, feelings of guilt, low self-worth, disturbed sleep or appetite, low energy, and poor concentration.

Psychopharmacological therapy as today's mainstream treatment has revolutionized the clinical management for major depressive disorders and has been shown to improve the quality of life for many patients. With that, these therapies are not effective for all patients. Results released from the Sequenced Treatment Alternatives to Relieve Depression Study (STAR\*D), conducted by the National Institute of Mental Health (NIMH), show that approximately 30% of depressed subjects respond to an SSRI in their first trial, despite adequate dosing and duration of treatment. The SSRI antidepressants do have a more favorable side effect profile than older medications, but they still may be difficult for some patients to tolerate because of gastrointestinal distress, anxiety, insomnia, and sexual dysfunction.

In addition to the psychopharmacologic treatments for depression, other therapies such as electroconvulsive therapy (ECT) and repetitive transcranial magnetic stimulation (rTMS) have been shown to have a therapeutic effect in MDD. ECT induces seizures electrically in anesthetized subjects. It is generally safe and effective; however the procedure can have the negative side effect of memory loss and confusion. Treatment with repetitive stimulation (rTMS) is intended to stimulate groups of cells in areas of the brain linked to MDD. While the therapy is non-invasive, it is expensive, involves a complex method for locating the point of stimulation in the brain, and has the potential for seizures.

rTMS uses magnetic pulses which causes neuronal activation of specific areas in the brain. It is generally believed that this activation causes resetting of cortical oscillators to create a therapeutic effect in MDD. The investigators hypothesize that TMS using low energy, sinusoidal magnetic fields synchronized to a patient's individual alpha frequency,(sTMS), can also affect neuronal activity leading to a reemergence of intrinsic rhythms and clinical improvement in MDD. Preliminary study results using sTMS have shown improvements in depressive symptoms with minimal side effects.

This multicenter study is designed to evaluate the safety and efficacy of sTMS in subjects with Major Depressive Disorder. Subjects will be randomized to receive treatment 5 days per week for 6 weeks. At the end of Treatment Week 6, subject will have completed the study treatments and will be offered open label sTMS therapy or alternate antidepressant treatment as clinically indicated. At minimum, subjects will be asked to return for one follow-up visit four weeks after their last double-blind treatment (Week 10) for evaluation and study completion.

Eligibility criteria: Inclusion Criteria:

* Subjects will meet the DSM-IV-TR primary diagnosis of initial or recurrent Major Depressive Disorder by DSM-IV-TR criteria rendered by structured interview using the Mini International Neuropsychiatric Interview (MINI).
* HAM-D17 score \>= 17 and Item 1 score greater than or equal to 2.
* Duration of current episode \>=8 weeks. The definition of an episode is demarcated by a period of \>=2 months when the subject did not meet full criteria for the DSM-IV-TR definition of Major Depressive Episode. Maximum duration of current episode cannot exceed 2 years.
* The baseline EEG is of sufficient duration and quality that it can be processed for quantitative analysis.
* Subjects are willing and able to adhere to the intensive treatment schedule and all required study visits.

Exclusion Criteria:

* Subjects are unable or unwilling to give informed consent.
* Diagnosed with the following conditions (current unless otherwise stated):

  * Any other current primary Axis I mood, anxiety, or psychotic disorder, including bipolar disorder.
  * Depression secondary to a general medical condition, or substance-induced.
  * History of substance abuse or dependence within the past 6 months (except nicotine and caffeine).
  * Any bipolar disorder or psychotic disorder (lifetime), including schizoaffective disorder, or major depression with psychotic features in this or previous episodes.
  * Eating disorder (current or within the past year).
  * Obsessive compulsive disorder (lifetime).
  * Post-traumatic stress disorder (current or within the past year).
  * ADHD (currently being treated).
* Subjects meeting criteria for Axis II cluster A or B diagnosis based upon DSM-IV TR criteria, which in the judgment of the Investigator may hinder the subjects in completing the procedures required by the study protocol.
* Subjects with a clinically defined neurological disorder including, but not limited to:

  * Any condition likely to be associated with increased intracranial pressure.
  * Space occupying brain lesion.
  * Any history of seizure EXCEPT those therapeutically induced by ECT (childhood febrile seizures are acceptable and these subjects may be included in the study).
  * History of stroke.
  * Transient ischemic attack within two years.
  * Cerebral aneurysm.
  * Dementia.
  * Mini Mental Status Exam (MMSE-2) score of =\<24.
  * Parkinson's disease.
  * Huntington's disease.
  * Multiple sclerosis.
  * Increased risk of seizure for any reason, including prior diagnosis of increased intracranial pressure (such as after large infarctions or trauma), or currently taking medication that lowers the seizure threshold. Medications that lower the seizure threshold are included in the Prohibited Concomitant Medication (Section 5.7).
* Subjects who are currently hospitalized due to severity of depression symptoms.
* Subjects with any of the following treatment histories:

  * TMS treatment within 6 months prior to the screening visit.
  * ECT treatment within 1 year prior to the screening visit.
  * Failure to respond to TMS or ECT treatment (i.e., consistent with ATHF confidence level 3 or higher) in this or any previous episode.
  * Lifetime history of treatment with Deep Brain Stimulation or Vagus Nerve Stimulation.
  * Use of any investigational drug or device within 4 weeks of the randomization visit.
  * Subjects who have been treated with fluoxetine within the past four weeks.
  * If participating in psychotherapy, must have been in stable treatment for at least 2 months prior to entry into the study, with no anticipation of change in the frequency of therapeutic sessions, or the therapeutic focus over the duration of the trial.
  * Failure to respond to Monoamine Oxidase Inhibitors (MAOIs) in the current episode.
* Use of any medication(s) listed on the Prohibited Concomitant Medication within 1 week of randomization.
* Subjects are adequately benefiting from current antidepressant medication(s).
* Significant acute suicide risk, defined as:

  * Suicide attempt within the previous 6 months that required medical treatment; or
  * Greater than or equal to 1 suicide attempts in the past 12 months; or
  * Has a clear-cut plan for suicide and states that he/she cannot guarantee that he/she will call his/her regular psychiatrist or the Investigator if the impulse to implement the plan becomes substantial during the study; or
  * In the Investigator's opinion, is likely to attempt suicide within the next 6 months.
* Cardiac pacemakers, implanted medication pumps, intracardiac lines, or acute, unstable cardiac disease.
* Intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, stents, or electrodes) or any other metal object within or near the head, excluding the mouth, which cannot be safely removed.
* Clinically significant abnormality or clinically significant unstable medical condition, as indicated by medical history, physical examination, ECG results, or clinical laboratory testing, that in the Investigator's judgment might pose a potential safety risk to the subject or limit interpretation of the trial results, e.g., any uncontrolled thyroid disorders, hepatic, cardiac, pulmonary and renal malfunctioning.
* Women who are currently pregnant or not using a medically acceptable means of birth control and women who are breastfeeding.
* Positive urine drug screen for illicit substances. (A positive urine drug screen at screening may be repeated once prior to randomization).
* Any condition which in the judgment of the Investigator would prevent the subject from completion of the study.

Primary outcomes:
measure: Mean HAM-D17 Total Score Change (Intent to Treat - All)
timeFrame: Baseline to End of Double-Blind Treatment Period (Week 6)
measure: Mean HAM-D17 Total Score Change (Per Protocol - All)
timeFrame: Baseline to End of Double-Blind Treatment Period (Week 6)
Secondary outcomes:
measure: Mean HAM-D17 Total Score Change (Per Protocol - Non-Naive Subjects)
timeFrame: Baseline to End of Double-Blind Treatment Period (Week 6)
measure: Number of Subjects Who Demonstrate Clinical Response at Week 6 or Early Termination (Intent to Treat)
timeFrame: Baseline to End of Double-Blind Treatment Period (Week 6)
measure: Number of Subjects Who Demonstrate Clinical Response at Week 6 (Per Protocol - All)
timeFrame: Baseline to End of Double-Blind Treatment Period (Week 6)
measure: Number of Subjects Who Demonstrate Clinical Response at Week 6 (Per Protocol - Non-Naive Subjects)
timeFrame: Baseline to End of Double-Blind Treatment Period (Week 6)
measure: Number of Subjects Who Demonstrate Clinical Remission at Week 6 or Early Termination (Intent to Treat)
timeFrame: Baseline to End of Double-Blind Treatment Period (Week 6)
measure: Number of Subjects Who Demonstrate Clinical Remission at Week 6 (Per Protocol - All)
timeFrame: Baseline to End of Double-Blind Treatment Period (up to week 6)
measure: Number of Subjects Who Demonstrate Clinical Remission at Week 6 or Early Termination (Per Protocol - Non-Naive Subjects)
timeFrame: Baseline to End of Double-Blind Treatment Period (Week 6)
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: UCLA Depression Research & Clinic Program
state: California
city: San Diego
country: United States
facility: UCSD Medical Center
state: California
city: Torrance
country: United States
facility: UCLA-Harbor
state: California
city: Hartford
country: United States
facility: Hartford Hospital Institute of Living
state: Connecticut
city: Chicago
country: United States
facility: TMS Specialists Chicago
state: Illinois
city: Baltimore
country: United States
facility: Sheppard Pratt Health System
state: Maryland
city: St. Louis
country: United States
facility: Washington University School of Medicine
state: Missouri
city: Omaha
country: United States
facility: University of Nebraska Medical Center
state: Nebraska
city: Cherry Hill
country: United States
facility: Center for Mood Disorders and Neuromodulation Therapies, UMDNJ-SOM
state: New Jersey
city: New York
country: United States
facility: Mount Sinai School of Medicine
state: New York
city: Durham
country: United States
facility: Duke University Brain Stimulation and Neurophysiology Center
state: North Carolina
city: Winston Salem
country: United States
facility: Wake Forest University Medical Center
state: North Carolina
city: Philadelphia
country: United States
facility: University of Pennsylvania
state: Pennsylvania
city: Pittsburgh
country: United States
facility: Mood Disorders Treatment Research Program University of Pittsburgh-Western Psychiatric Institute and Clinic
state: Pennsylvania
city: Providence
country: United States
facility: Butler Hospital Mood Disorders Research Program, Brown Department of Psychiatry and Human Behavior
state: Rhode Island
city: Charleston
country: United States
facility: MUSC Institute of Psychiatry, Brain Stimulation Lab
state: South Carolina
city: Dallas
country: United States
facility: UT Southwestern Medical Center
state: Texas
city: Lake Jackson
country: United States
facility: R/D Clinical Research
state: Texas
Study officials:
affiliation: UCLA Depression Research & Clinic Program
name: Andrew Leuchter, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Leuchter AF, Cook IA, Feifel D, Goethe JW, Husain M, Carpenter LL, Thase ME, Krystal AD, Philip NS, Bhati MT, Burke WJ, Howland RH, Sheline YI, Aaronson ST, Iosifescu DV, O'Reardon JP, Gilmer WS, Jain R, Burgoyne KS, Phillips B, Manberg PJ, Massaro J, Hunter AM, Lisanby SH, George MS. Efficacy and Safety of Low-field Synchronized Transcranial Magnetic Stimulation (sTMS) for Treatment of Major Depression. Brain Stimul. 2015 Jul-Aug;8(4):787-94. doi: 10.1016/j.brs.2015.05.005. Epub 2015 May 22.